Search results
Aug 11, 2022 · In the ALFA+ cohort, all tested plasma biomarkers (p-tau181, p-tau217, p-tau231, GFAP, NfL and Aβ42/40) were significantly changed in preclinical Alzheimer’s disease.
Jul 6, 2024 · Plasma tau phosphorylated at threonine-217 (P-tau217) presents a promising alternative, yet optimal cutoffs for treatment eligibility with DMTs like aducanumab require further investigation. This study evaluates the efficacy of one- and two-cutoff strategies for determining DMT eligibility at the Butler Hospital Memory & Aging Program (MAP).
Plasma P-tau217 and P-tau181 are associated with Alzheimer’s disease (AD) tau pathology. P-tau217 is a more novel blood-based biomarker that may be diagnostically superior to P-tau181.
Sep 13, 2024 · Plasma biomarkers of dementia, including phosphorylated tau (p-tau217), offer promise as tools for diagnosis, stratification for clinical trials, monitoring disease progression, and...
Jun 14, 2022 · Plasma p-tau217 demonstrated high accuracy in predicting abnormal Aβ-PET signal (centiloid >24) in TRIAD (AUC, 0.92; 95% CI, 0.92-0.96) and WRAP (AUC, 0.93; 95% CI, 0.90-0.97) (Figure 2A). In SPIN, p-tau217 also had high accuracy in predicting abnormal CSF Aβ42/40 (AUC, 0.96; 95% CI, 0.92-0.99) (Figure 2A).
Feb 21, 2024 · Plasma %p-tau217 was clinically equivalent to FDA-approved CSF tests in classifying Aβ PET status, with an area under the curve (AUC) for both between 0.95 and 0.97. Plasma %p-tau217 was...
Aug 19, 2024 · Plasma p-tau217 has emerged as the most promising blood-based marker (BBM) for the detection of Alzheimer Disease (AD) pathology, yet few studies have evaluated plasma p-tau217 performance in memory clinic settings.
